Skip to main content

Acute Graft Versus Host Disease

3
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
pentostatinPhase 3Small Molecule3 trials
Active Trials
NCT00144430Completed60Est. Aug 2008
NCT00032773Terminated36Est. Nov 2005
NCT00506922Completed150Est. Nov 2009
Design Pharmaceuticals
1 program
1
Adult Allogeneic Mesenchymal cells from adipose tissue.Phase 1/21 trial
Active Trials
NCT02687646Completed16Est. Jan 2022
Sandoz
SandozAustria - Kundl
1 program
1
RuxolitinibPhase 1/2Small Molecule1 trial
Active Trials
NCT03491215Completed45Est. Feb 2023
Design Therapeutics
1 program
Adult Allogeneic Mesenchymal cells from adipose tissue.PHASE_1_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Astex Pharmaceuticalspentostatin
SandozRuxolitinib
Design PharmaceuticalsAdult Allogeneic Mesenchymal cells from adipose tissue.
Astex Pharmaceuticalspentostatin
Astex Pharmaceuticalspentostatin

Clinical Trials (5)

Total enrollment: 307 patients across 5 trials

NCT00144430Astex Pharmaceuticalspentostatin

Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children

Start: Jan 2004Est. completion: Aug 200860 patients
Phase 2Completed
NCT03491215SandozRuxolitinib

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Start: Feb 2019Est. completion: Feb 202345 patients
Phase 1/2Completed
NCT02687646Design PharmaceuticalsAdult Allogeneic Mesenchymal cells from adipose tissue.

Clinical Trial With MSC for Graft Versus Host Disease Treatment

Start: Feb 2017Est. completion: Jan 202216 patients
Phase 1/2Completed
NCT00032773Astex Pharmaceuticalspentostatin

Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

Start: Jan 2002Est. completion: Nov 200536 patients
Phase 1/2Terminated
NCT00506922Astex Pharmaceuticalspentostatin

Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT

Start: Sep 2000Est. completion: Nov 2009150 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.